BioWorld

ATLANTA, April 8, 2013 /PRNewswire-USNewswire/ -- Biotech companies generated $5 billion in the first quarter of 2013, just 3% less than the $5.15 billion raised in the first quarter last year. The heavy lifting for the period was carried out by public companies, which were responsible for ... read more

ATLANTA, Feb. 27, 2013 /PRNewswire-USNewswire/ -- Makers of innovative biologics have legitimate reason to sound alarms about automatic substitution of biosimilars that have not proven their interchangeability - and it's not just because of the potential impact to their bottom line. That point was driven home by ... read more

ATLANTA, Jan. 24, 2013 /PRNewswire-USNewswire/ -- The quiet but growing flood of biosimilars ? new versions of existing biopharmaceutical drugs ? promises to reduce the overall costs of delivering highly effective biotechnology-based medicines, but it's also a game changer for the entire drug development industry akin to the impact generics ... read more

ATLANTA, Dec. 27, 2012 /PRNewswire-USNewswire/ -- Biotechnology played a pivotal role in the development of more targeted drugs in 2012 as the science continues to elucidate the molecular mechanisms of diseases. The volatile biopharmaceutical industry ? historically comprised of venture-backed start-ups ? produced some whopping news in ... read more